Literature DB >> 11448576

Predictors of survival in terminal-cancer patients with irreversible bowel obstruction receiving home parenteral nutrition.

F Pasanisi1, A Orban, L Scalfi, L Alfonsi, L Santarpia, E Zurlo, A Celona, A Potenza, F Contaldo.   

Abstract

Clinical, anthropometric, hematologic, and biochemical variables, evaluated immediately before starting nutritional treatment, were related to survival in 76 terminal-cancer patients with irreversible bowel obstruction receiving home parenteral nutrition. At baseline, abnormally low values were observed in the following percentages of patients: 40.8% for body mass index, 59.2% for serum albumin, 84.2% for hemoglobin, 48.7% for lymphocyte count, and 60% for serum cholesterol. Survival on home parenteral nutrition ranged between 6 and 301 d, with a median of 74 d. Hemoglobin, serum albumin and serum cholesterol were lower in patients with a survival of less than 3 mo. With regard to Karnofsky performance status, median survival times were 63 d for a score below or equal to 50 and 128 d for a score between 60 and 70. Albumin and a Karnofsky score above 50 (but not age, weight, body mass index, lymphocyte count, or cholesterol) emerged (with a positive sign) as predictors of survival. In conclusion, terminal-cancer patients with irreversible bowel obstruction are often malnourished, showing a high prevalence of anemia and hypoalbuminemia. Survival differs widely and can be predicted only to a limited extent from initial values of serum albumin and Karnofsky performance status.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448576     DOI: 10.1016/s0899-9007(01)00579-2

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  13 in total

Review 1.  Home parenteral nutrition for people with inoperable malignant bowel obstruction.

Authors:  Anne Marie Sowerbutts; Simon Lal; Jana Sremanakova; Andrew Clamp; Chris Todd; Gordon C Jayson; Antje Teubner; Anne-Marie Raftery; Eileen J Sutton; Lisa Hardy; Sorrel Burden
Journal:  Cochrane Database Syst Rev       Date:  2018-08-10

2.  A pharmacokinetic model for the glycation of albumin.

Authors:  Oskar Alskär; Julia Korell; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-04-21       Impact factor: 2.745

Review 3.  The role of parenteral nutrition in patients with malignant bowel obstruction.

Authors:  Federico Bozzetti
Journal:  Support Care Cancer       Date:  2019-07-17       Impact factor: 3.603

4.  The Chicago Consensus on Peritoneal Surface Malignancies: Palliative Care Considerations.

Authors: 
Journal:  Ann Surg Oncol       Date:  2020-04-13       Impact factor: 5.344

Review 5.  Recent advances in malignant bowel obstruction: an interface of old and new.

Authors:  Vinaya Potluri; Donna S Zhukovsky
Journal:  Curr Pain Headache Rep       Date:  2003-08

6.  Predicting survival time in noncurative patients with advanced cancer: a prospective study in China.

Authors:  Jing Cui; Lingjun Zhou; B Wee; Fengping Shen; Xiuqiang Ma; Jijun Zhao
Journal:  J Palliat Med       Date:  2014-04-07       Impact factor: 2.947

7.  Exogenous albumin inhibits sorafenib-induced cytotoxicity in human cancer cell lines.

Authors:  Syu-Ichi Kanno; Katsuyuki Itoh; Naoto Suzuki; Ayako Tomizawa; Shin Yomogida; Masaaki Ishikawa
Journal:  Mol Clin Oncol       Date:  2012-06-27

Review 8.  Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature.

Authors:  Digant Gupta; Christopher G Lis
Journal:  Nutr J       Date:  2010-12-22       Impact factor: 3.271

9.  Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction.

Authors:  Jay Chouhan; Rohan Gupta; Joe Ensor; Kanwal Raghav; David Fogelman; Robert A Wolff; Michael Fisch; Michael J Overman
Journal:  Cancer Med       Date:  2015-12-29       Impact factor: 4.452

10.  Factors Associated with Short-Term Mortality After Surgical Oncologic Emergencies.

Authors:  Marianne R F Bosscher; Esther Bastiaannet; Barbara L van Leeuwen; Harald J Hoekstra
Journal:  Ann Surg Oncol       Date:  2015-11-09       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.